Advertisement

Topics

TMB as New Biomarker in NSCLC -- Ready for Clinic?

04:08 EDT 17 Apr 2018 | Medscape

A new biomarker -- high tumor mutational burden (TMB) -- identifies lung cancer patients who do better on immunotherapy than on chemotherapy.
Medscape Medical News

Original Article: TMB as New Biomarker in NSCLC -- Ready for Clinic?

NEXT ARTICLE

More From BioPortfolio on "TMB as New Biomarker in NSCLC -- Ready for Clinic?"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...